Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CCR5 | P51681 | 4/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14272921 | 0.91 | OPRM1 (0.47) | OPRM1CCR5MEN1KMT2APDE4A | |
| SCHEMBL191571 | 0.90 | OPRM1 (0.46) | OPRM1MEN1KMT2ATACR1 | |
| SCHEMBL651457 | 0.87 | OPRM1 (0.56) | OPRM1MEN1KMT2APOLB | |
| SCHEMBL31158359 | 0.85 | STS (0.47) | CCR5MEN1KMT2ATACR1ALOX15 | |
| SCHEMBL2573823 | 0.85 | STS (0.47) | CCR5MEN1KMT2ATACR1ALOX15 | |
| SCHEMBL27225781 | 0.84 | JAK2 (0.47) | TACR1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22509312 | 0.83 | OPRM1 (0.55) | OPRM1MEN1KMT2AALOX15TSHR | |
| SCHEMBL654359 | 0.83 | CCR5 (0.47) | CCR5MEN1KMT2ATACR1ALOX15 | |
| SCHEMBL8350419 | 0.83 | OPRM1 (0.59) | OPRM1OPRL1KMT2ATACR1PDE4A | |
| SCHEMBL4657423 | 0.83 | OPRM1 (0.67) | OPRM1SLC6A4SLC6A3OPRL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170015654-A1 | PYRIDAZINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | disclosed |
| EP-3118200-A1 | PYRIDAZINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2771322-A2 | NOVEL TRPV3 MODULATORS | AbbVie Inc. (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772499-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2014-03-20 | — | — | US | disclosed |
| EP-2681215-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | GENETECH, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2012118850-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1581495-B1 | 4-aryl-4-(naphth-1-ylmethylamino)methyl-piperidine compounds and their use | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| US-20060058352-A1 | Piperidine amine compounds and their use | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1581495-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1549615-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004056771-A1 | PIPERIDINE AMINE COMPOUNDS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | OPRM1 4778/4885SLC6A4 4817/4885SLC6A3 4577/4885 |
| US-20060058352-A1 | Piperidine amine compounds and their use | HRH3, H1-5, H1-0 | OPRM1 161/4885SLC6A4 752/4885SLC6A3 1270/4885 |
| US-20170015654-A1 | PYRIDAZINE COMPOUND | SCD, SCD5, FADS2 | OPRM1 3911/4885SLC6A4 2421/4885SLC6A3 3698/4885 |
| US-20140080803-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | OPRM1 121/4885SLC6A4 498/4885SLC6A3 747/4885 |
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | OPRM1 696/4885SLC6A4 1749/4885SLC6A3 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.